CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

Lung Cancer

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC

Where do we stand with mCRPC?

PARPi combinations to treat patients with mCRPC

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer

Sotorasib and panitumumab demonstrate clinically meaningful benefit in KRAS G12C-mutated metastatic colorectal cancer 

Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer